Skip to main content
Top
Published in: Immunologic Research 5/2021

01-10-2021 | Ebola Virus | Commentary

COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators

Author: Mina T. Kelleni

Published in: Immunologic Research | Issue 5/2021

Login to get access

Abstract

In this manuscript, COVID-19, Ebola virus disease, Nipah virus infection, SARS, and MERS are suggested to be considered for a novel immunological reclassification as acute onset immune dysrhythmia syndrome (n-AIDS) due to altered monocytic, Th1/Th2, as well as cytokines and chemokines balances. n-AIDs is postulated to be the cause of the acute respiratory distress and multi-inflammatory syndromes which are described with fatal COVID-19, and immunomodulators are suggested to effectively manage the mentioned diseases as well as for other disorders caused by Th1/Th2 imbalance. Meanwhile, para COVID syndrome is suggested to describe various immune-related complications, whether before or after recovery, and to embrace a potential of a latent infection, that might be discovered later, as occurred with Ebola virus disease. Finally, our hypothesis has evolved out of our real-life practice that uses immunomodulatory drugs to manage COVID-19 safely and effectively.
Literature
1.
go back to reference Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14(3):107–11.CrossRef Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14(3):107–11.CrossRef
3.
go back to reference Rupp J, et al. T cell phenotyping in individuals hospitalized with COVID-19. J Immunol. 2021;206:1478.CrossRef Rupp J, et al. T cell phenotyping in individuals hospitalized with COVID-19. J Immunol. 2021;206:1478.CrossRef
4.
go back to reference Zheng M, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–5.CrossRef Zheng M, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–5.CrossRef
5.
go back to reference Sami R, et al. Characterizing the immune responses of those who survived or succumbed to COVID-19: can immunological signatures predict outcome? Cytokine. 2021;140:155439.CrossRef Sami R, et al. Characterizing the immune responses of those who survived or succumbed to COVID-19: can immunological signatures predict outcome? Cytokine. 2021;140:155439.CrossRef
6.
go back to reference Gupta A. Is immuno-modulation the key to COVID-19 pandemic? Indian J Orthopaedics. 2020;54(3):394–7.CrossRef Gupta A. Is immuno-modulation the key to COVID-19 pandemic? Indian J Orthopaedics. 2020;54(3):394–7.CrossRef
7.
go back to reference Neidleman J, et al. Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. MedRxiv. 2021;587:270. Neidleman J, et al. Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. MedRxiv. 2021;587:270.
8.
go back to reference Gadotti AC, et al. IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res. 2020;289:198171–198171.CrossRef Gadotti AC, et al. IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res. 2020;289:198171–198171.CrossRef
9.
go back to reference Galani I-E, et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat Immunol. 2021;22(1):32–40.CrossRef Galani I-E, et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat Immunol. 2021;22(1):32–40.CrossRef
10.
go back to reference Lopez L, et al. Dysregulated interferon response underlying severe COVID-19. Viruses. 2020;12(12):1433.CrossRef Lopez L, et al. Dysregulated interferon response underlying severe COVID-19. Viruses. 2020;12(12):1433.CrossRef
12.
go back to reference Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585.CrossRef Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585.CrossRef
13.
go back to reference Luo J, et al. The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2. Gene. 2021;768:145325.CrossRef Luo J, et al. The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2. Gene. 2021;768:145325.CrossRef
15.
go back to reference Pairo-Castineira E, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2020;591:92–8.CrossRef Pairo-Castineira E, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2020;591:92–8.CrossRef
17.
go back to reference Lou B, et al. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. Eur Respir J. 2020;56:2000763.CrossRef Lou B, et al. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. Eur Respir J. 2020;56:2000763.CrossRef
19.
go back to reference Cañas CA. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses. 2020;145:110345.CrossRef Cañas CA. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses. 2020;145:110345.CrossRef
20.
go back to reference Blanco-Melo D, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–45.e1039.CrossRef Blanco-Melo D, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–45.e1039.CrossRef
22.
go back to reference Pietsch H, et al. Proof of SARS-CoV-2 genomes in endomyocardial biopsy with latency after acute infection. Int J Infect Dis. 2021;102:70–2.CrossRef Pietsch H, et al. Proof of SARS-CoV-2 genomes in endomyocardial biopsy with latency after acute infection. Int J Infect Dis. 2021;102:70–2.CrossRef
23.
go back to reference Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020;16(11):636–44.CrossRef Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020;16(11):636–44.CrossRef
24.
go back to reference Taquet M, et al. 6-month neurological and psychiatric outcomes in survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–27.CrossRef Taquet M, et al. 6-month neurological and psychiatric outcomes in survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–27.CrossRef
25.
go back to reference Simonnet A, et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now. 2021;51:296.CrossRef Simonnet A, et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now. 2021;51:296.CrossRef
26.
go back to reference Tavazzi G, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911–5.CrossRef Tavazzi G, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911–5.CrossRef
27.
go back to reference Liegeois M, et al. The interstitial macrophage: a long-neglected piece in the puzzle of lung immunity. Cell Immunol. 2018;330:91–6.CrossRef Liegeois M, et al. The interstitial macrophage: a long-neglected piece in the puzzle of lung immunity. Cell Immunol. 2018;330:91–6.CrossRef
28.
go back to reference Falasca L, et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ. 2015;22(8):1250–9.CrossRef Falasca L, et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ. 2015;22(8):1250–9.CrossRef
29.
go back to reference Wiedemann A, et al. Long-lasting severe immune dysfunction in Ebola virus disease survivors. Nat Commun. 2020;11(1):3730.CrossRef Wiedemann A, et al. Long-lasting severe immune dysfunction in Ebola virus disease survivors. Nat Commun. 2020;11(1):3730.CrossRef
30.
go back to reference Colavita F, et al. Inflammatory and humoral immune response during Ebola virus infection in survivor and fatal cases occurred in Sierra Leone during the 2014–2016 outbreak in West Africa. Viruses. 2019;11(4):373.CrossRef Colavita F, et al. Inflammatory and humoral immune response during Ebola virus infection in survivor and fatal cases occurred in Sierra Leone during the 2014–2016 outbreak in West Africa. Viruses. 2019;11(4):373.CrossRef
32.
go back to reference Satterfield BA, et al. The immunomodulating V and W proteins of Nipah virus determine disease course. Nat Commun. 2015;6(1):7483.CrossRef Satterfield BA, et al. The immunomodulating V and W proteins of Nipah virus determine disease course. Nat Commun. 2015;6(1):7483.CrossRef
33.
go back to reference Prescott J, et al. The immune response to Nipah virus infection. Adv Virol. 2012;157(9):1635–41. Prescott J, et al. The immune response to Nipah virus infection. Adv Virol. 2012;157(9):1635–41.
34.
go back to reference Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother. 2021;133:110982.CrossRef Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother. 2021;133:110982.CrossRef
35.
go back to reference Saleemi MA, et al. Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2020;85:104583–104583. Saleemi MA, et al. Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2020;85:104583–104583.
36.
go back to reference Roe K. Explanation for COVID-19 infection neurological damage and reactivations. Transbound Emerg Dis. 2020;67(4):1414–5.CrossRef Roe K. Explanation for COVID-19 infection neurological damage and reactivations. Transbound Emerg Dis. 2020;67(4):1414–5.CrossRef
38.
go back to reference Bixler SL, et al. Discovering drugs for the treatment of Ebola virus. Curr Treat Options Infect Dis. 2017;9(3):299–317.CrossRef Bixler SL, et al. Discovering drugs for the treatment of Ebola virus. Curr Treat Options Infect Dis. 2017;9(3):299–317.CrossRef
Metadata
Title
COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators
Author
Mina T. Kelleni
Publication date
01-10-2021
Publisher
Springer US
Published in
Immunologic Research / Issue 5/2021
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-021-09219-y

Other articles of this Issue 5/2021

Immunologic Research 5/2021 Go to the issue